The FDA approved galcanezumab-gnlm (Emgality, Lilly) solution for injection for the treatment of episodic cluster headache in adults.
“Emgality provides patients with the first FDA-approved drug that reduces the frequency of attacks of episodic cluster headache, an extremely painful and often debilitating condition,” said Eric Bastings, MD, the deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “The FDA is committed